Midwest Trust 13F: Cuts Zoetis (ZTS) Stake by $8M

Midwest Trust trimmed its position in Zoetis Inc. ZTS by 114,689 shares during the quarter, according to a Form 13F filing with the SEC filed on October 22, 2026.

ZTS Zoetis Inc.

$79.62 ▼ -35.78% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in Midwest Trust's Zoetis Inc. Position

The firm cut its holdings by 92.4%, leaving it with 9,372 shares of the animal health company. That remaining stake had a value of $654,447 at the end of the reporting period, down from its prior total of 124,061 shares.

Other Institutional Activity in Zoetis Inc.

Other major investors also adjusted their holdings in the stock during recent periods. Fideuram - Intesa Sanpaolo Private Banking S.P.A. grew its holdings by 101,852 shares, ending with 265,022 shares worth about $18,506,492. Moran Wealth Management grew its holdings by 35,213 shares, ending with 445,975 shares worth about $31,142,424. State Farm Mutual Automobile Insurance Co held steady with 15,892,903 shares valued at about $1,303,218,046. Nordea Investment Management AB grew its holdings by 727,295 shares, ending with 6,592,578 shares worth about $540,591,396. Deutsche Bank AG grew its holdings by 319,749 shares, ending with 5,851,737 shares worth about $479,842,434.

Zoetis Inc. Stock Up 2.4%

Zoetis shares recently traded around $81.99, close to their closing price of $82.00 on October 22, 2026. The stock trades above its 50-day moving average of $74.31 but sits below its 200-day moving average of $95.16. The company has a market capitalization of roughly $32.9 billion and a trailing P/E ratio of 13.1.

Recent Earnings

Zoetis reported trailing twelve-month revenue of $9.53 billion and earnings of $6.08 per share. The company generated a net profit margin of 27.7% and a return on equity of 64.9%. Its next quarterly earnings report is scheduled for November 5, 2026.

Dividend

Zoetis pays an annual dividend of $2.12 per share. This payout gives the stock a dividend yield of 2.66% based on recent trading levels. The company's dividend payout ratio sits at 33.9%, meaning it uses about a third of its earnings to fund the payout to shareholders.

Insider Buying and Selling at Zoetis Inc.

Company insiders made several share purchases earlier in the year. Director Michael B. McCallister bought 3,000 shares on May 11, 2026, at an average price of $77.76 for a total of $233,273. Director Paul M. Bisaro bought 2,000 shares on May 13, 2026, at an average price of $75.88 for a total of $151,750. Director Frank A. D. Amelio acquired 6,650 shares on May 13, 2026, at an average price of $75.39 for a total of $501,344.

Analysts Set New Price Targets

Wall Street research firms updated their views on the stock ahead of upcoming results. Citigroup maintained a buy rating with a target of $96.00 on August 11, 2026. Stifel maintained a hold rating with a target of $80.00 on August 20, 2026. TD Cowen maintained a buy rating with a target of $94.00 on August 25, 2026. Goldman Sachs initiated coverage with a neutral rating and a $74.00 target on October 16, 2026. Jefferies downgraded the stock to a hold and cut its target to $83.00 on October 20, 2026. Overall, the stock carries a consensus buy rating with a mean price target of $93.00 across 14 analyst opinions.

About Zoetis Inc.

Zoetis develops and manufactures medicines, vaccines, and diagnostic products for both companion animals like dogs and cats and livestock species including cattle and pigs. The company operates across the global animal health sector, providing veterinarians and livestock producers with diagnostics, biodevices, and genetic tests.

Bottom Line

Investors will look to the upcoming earnings release on November 5, 2026, for further insight into the company's financial health following these institutional portfolio changes.